Immune cell therapy for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have locally advanced or metastatic pancreatic cancer that can't be cured with standard treatments.
- You've had at least one type of chemotherapy (like gemcitabine or 5FU) and your cancer has been stable or improved for at least 3 months.
- You have cancer that can be measured on scans.
- You are in good general health (able to do daily activities without help) and are 18 or older.
- You are not pregnant, plan to use effective birth control during and for 90 days after treatment, and are not breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It may be an option if you have already tried at least one previous treatment or if you have not had any treatment yet, depending on the study group.
This trial tests a new treatment for people with advanced pancreatic cancer that has spread and is not removable by surgery, after standard treatments like chemotherapy no longer work. The goal is to see if this experimental therapy can help shrink tumors or slow the disease.
This trial tests an experimental cell therapy called MT-601 for people with advanced pancreatic cancer that has not worsened during standard chemotherapy (FOLFIRINOX or nab-paclitaxel/gemcitabine). The goal is to see if this new treatment can help control the cancer.
This trial tests a combination of radiation therapy (SBRT), two immunotherapy drugs (Ipilimumab and Sintilimab), and two chemotherapy drugs (Nab-Paclitaxel and Gemcitabine) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this treatment can control the cancer better than standard options.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial tests a new immunotherapy drug (adebrelimab) combined with a standard chemotherapy cocktail (NALIRIFOX) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination shrinks or controls the cancer better than chemo alone.
Hear when a new Pancreas Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.